Overview

Effect of Food on Blood Levels of ASTX727

Status:
Completed

Trial end date:
2019-12-16

Target enrollment:

Participant gender:

Summary

This study is designed to examine blood levels of ASTX727, a fixed-dose combination tablet containing the combination of cedazuridine (100 mg) and decitabine (35 mg), when given under fed versus fasted conditions to participants with myelodysplastic syndromes (MDS), including refractory anemia with excess blasts in transformation or chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). This study will also assess the safety of ASTX727.

Phase:

Phase 1

Details

Lead Sponsor:

Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.

Treatments:

Azacitidine
Decitabine